Cognitive Behavioral Therapy + Alternative Selective Serotonin Reuptake Inhibitor Better than Alternative SSRI Alone in Adolescent Depression

2008 ◽  
Vol 100 (6) ◽  
pp. 762-763
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Adolescent Depression ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Selective Serotonin ◽  
Serotonin Reuptake Inhibitor ◽  
Better Than

scholarly journals Severe Hyperacusis, Photophobia, and Skin Hypersensitivity

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Alessandra Barbara Fioretti ◽  
Theodoros Varakliotis ◽  
Otello Poli ◽  
Manuela Cantagallo ◽  
Alberto Eibenstein
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Medical Therapy ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Selective Serotonin ◽  
Skin Hypersensitivity ◽  
Sound Therapy

We report a case of a patient with severe hyperacusis, photophobia, and skin hypersensitivity. The patient was initially treated with sound therapy and medical therapy for 4 months and successfully with a selective serotonin reuptake inhibitor (SSRI) and cognitive behavioral therapy which improved her mood and the tolerance for sounds and light.

Insight and Delusional Beliefs in Body Dysmorphic Disorder

2017 ◽  
Author(s):  
Katharine A. Phillips
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Psychotic Disorder ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Body Dysmorphic Disorder ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Serotonin Reuptake Inhibitor

This chapter discusses insight (“delusionality”) in body dysmorphic disorder (BDD). BDD beliefs span a broad range of insight, from good to absent insight (i.e., delusional beliefs). About 70% of patients have poor or absent insight. Early emerging clues suggest possible neurobiologic bases of poorer insight in BDD. BDD’s delusional form (characterized by the absence of insight) appears to be the same disorder as its nondelusional form rather than a separate psychotic disorder. Consistent with this, serotonin-reuptake inhibitor (SRI) monotherapy is efficacious for delusional BDD as well as nondelusional BDD. Neuroleptic (antipsychotic) monotherapy is not currently recommended for delusional BDD. Cognitive-behavioral therapy (CBT) appears efficacious for both delusional and nondelusional BDD, but research is needed to determine whether a somewhat modified approach may be helpful for delusional beliefs. Insight often improves with SRIs and CBT.

Sign in / Sign up

Export Citation Format

Share Document